NASDAQ:XOMA - Xoma Stock Price, Price Target & More

$23.53 +0.21 (+0.90 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$23.53
Today's Range$22.85 - $23.78
52-Week Range$5.86 - $37.25
Volume73,942 shs
Average Volume173,917 shs
Market Capitalization$188.64 million
P/E Ratio24.01
Dividend YieldN/A
Beta3.05

About Xoma (NASDAQ:XOMA)

Xoma logoXOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Debt-to-Equity Ratio2.52%
Current Ratio5.96%
Quick Ratio5.96%

Price-To-Earnings

Trailing P/E Ratio24.01
Forward P/E Ratio-18.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.69 million
Price / Sales3.72
Cash Flow$2.2094 per share
Price / Cash10.65
Book Value$0.71 per share
Price / Book33.14

Profitability

EPS (Most Recent Fiscal Year)$0.98
Net Income$14.59 million
Net Margins27.49%
Return on Equity-130.44%
Return on Assets46.59%

Miscellaneous

Employees12
Outstanding Shares8,330,000

How to Become a New Pot Stock Millionaire

Xoma (NASDAQ:XOMA) Frequently Asked Questions

What is Xoma's stock symbol?

Xoma trades on the NASDAQ under the ticker symbol "XOMA."

How were Xoma's earnings last quarter?

Xoma Co. (NASDAQ:XOMA) announced its quarterly earnings data on Wednesday, March, 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.19. The biotechnology company earned $5.36 million during the quarter, compared to analyst estimates of $4.12 million. Xoma had a net margin of 27.49% and a negative return on equity of 130.44%. View Xoma's Earnings History.

When is Xoma's next earnings date?

Xoma is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Xoma.

What price target have analysts set for XOMA?

2 Wall Street analysts have issued 1-year target prices for Xoma's shares. Their predictions range from $33.00 to $49.00. On average, they expect Xoma's stock price to reach $41.00 in the next year. View Analyst Ratings for Xoma.

Who are some of Xoma's key competitors?

Who are Xoma's key executives?

Xoma's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 62)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)
  • Dr. Deepshikha Datta, Chief Bus. Officer
  • Dr. Kirk W. Johnson Ph.D., VP of Devel. (Age 58)

Has Xoma been receiving favorable news coverage?

News headlines about XOMA stock have been trending somewhat positive on Thursday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Xoma earned a coverage optimism score of 0.12 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.74 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Xoma?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xoma's stock price today?

One share of XOMA stock can currently be purchased for approximately $23.53.

How big of a company is Xoma?

Xoma has a market capitalization of $188.64 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. Xoma employs 12 workers across the globe.

How can I contact Xoma?

Xoma's mailing address is 2910 SEVENTH ST, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for Xoma (XOMA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Xoma and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xoma (NASDAQ:XOMA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Xoma in the last 12 months. Their average twelve-month price target is $41.00, suggesting that the stock has a possible upside of 74.25%. The high price target for XOMA is $49.00 and the low price target for XOMA is $33.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.00$41.00$41.00$28.50
Price Target Upside: 74.25% upside86.36% upside25.65% upside29.31% upside

Xoma (NASDAQ:XOMA) Consensus Price Target History

Price Target History for Xoma (NASDAQ:XOMA)

Xoma (NASDAQ:XOMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightSet Price TargetBuy$49.00HighView Rating Details
12/19/2017WedbushReiterated RatingBuy$33.00LowView Rating Details
2/1/2017CowenReiterated RatingHoldN/AView Rating Details
11/16/2016Ladenburg ThalmannReiterated RatingNeutralN/AView Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Xoma (NASDAQ:XOMA) Earnings History and Estimates Chart

Earnings by Quarter for Xoma (NASDAQ:XOMA)

Xoma (NASDAQ:XOMA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.54)($0.54)($0.54)
Q4 20181($0.27)($0.27)($0.27)

Xoma (NASDAQ XOMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
3/7/2018Q4 2017($0.35)($0.16)$4.12 million$5.36 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.81)$1.98$17.95 million$36.18 millionViewN/AView Earnings Details
8/8/2017Q2 2017$0.34$0.21$10.56 million$10.89 millionViewN/AView Earnings Details
5/9/2017Q1 2017($1.30)($2.30)$0.96 million$0.26 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.32)($2.89)$0.50 million$0.50 millionViewN/AView Earnings Details
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)$1.17 million$3.96 millionViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($3.40)($3.00)$9.42 million$9.45 millionViewN/AView Earnings Details
3/12/2013Q4 2012($4.80)($3.60)ViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
8/7/2012Q2 2012($4.40)($4.60)ViewN/AView Earnings Details
5/8/2012Q1 2012($5.20)($5.54)ViewN/AView Earnings Details
3/14/2012Q4 2011($5.00)($6.82)ViewN/AView Earnings Details
11/9/2011Q3 2011($6.40)($4.00)ViewN/AView Earnings Details
8/4/2011Q2 2011($4.80)($5.44)ViewN/AView Earnings Details
5/5/2011Q1 2011($8.80)($4.34)ViewN/AView Earnings Details
3/10/2011Q4 2010($14.60)($16.76)ViewN/AView Earnings Details
11/4/2010Q3 2010($16.80)($13.76)ViewN/AView Earnings Details
8/9/2010Q2 2010($20.99)($18.59)ViewN/AView Earnings Details
5/6/2010Q1 2010($17.99)($27.29)ViewN/AView Earnings Details
3/11/2010Q4 2009($9.00)$4.50ViewN/AView Earnings Details
11/9/2009Q3 2009$2.70ViewN/AView Earnings Details
8/6/2009Q2 2009($26.99)($19.79)ViewN/AView Earnings Details
5/7/2009Q1 2009$3.00$16.49ViewN/AView Earnings Details
11/10/2008Q3 2008($26.99)($46.18)ViewN/AView Earnings Details
8/7/2008Q2 2008($29.99)($46.78)ViewN/AView Earnings Details
5/12/2008Q1 2008($17.99)($32.08)ViewN/AView Earnings Details
3/11/2008Q4 2007($32.98)($20.99)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Xoma (NASDAQ:XOMA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Xoma (NASDAQ XOMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 38.85%
Insider Trading History for Xoma (NASDAQ:XOMA)
Insider Trading History for Xoma (NASDAQ:XOMA)

Xoma (NASDAQ XOMA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017James R. NealCEOSell46,296$28.24$1,307,399.04View SEC Filing  
11/15/2017Thomas M BurnsSVPSell22,222$28.69$637,549.1813,538View SEC Filing  
11/13/2017James R. NealCEOSell11,568$30.83$356,641.44View SEC Filing  
11/13/2017Thomas M BurnsCFOSell6,983$30.99$216,403.1713,538View SEC Filing  
5/16/2017John VarianDirectorSell39,540$6.24$246,729.602,344View SEC Filing  
3/21/2017James R. NealVPSell5,105$5.40$27,567.00View SEC Filing  
2/1/2017James R NealVPSell195$4.52$881.4020,566View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.7541,884View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.508,217View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.161,189,695View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30243,727View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32350,795View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.0094,227View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00102,227View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00110,227View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00118,227View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00285,613View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00285,613View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.8062,600View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28285,613View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.0891,546View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.1990,719View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.8093,150View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00270,035View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00148,739View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.003,228View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.003,228View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00148,739View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.0042,017View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.003,534View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00148,739View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.0042,017View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.843,534View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.323,534View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40148,739View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00103,006View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.008,329View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00103,006View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.0014,329View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89103,006View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.2811,820View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.7227,711View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.2020,329View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Xoma (NASDAQ XOMA) News Headlines

Source:
DateHeadline
XOMA (XOMA) Upgraded by ValuEngine to SellXOMA (XOMA) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 19 at 11:31 AM
Valideas Top Five Healthcare Stocks Based On David Dreman - 4/15/2018Validea's Top Five Healthcare Stocks Based On David Dreman - 4/15/2018
www.nasdaq.com - April 16 at 9:52 AM
XOMA (XOMA) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowXOMA (XOMA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 12 at 10:39 AM
XOMA (XOMA) Downgraded to D at TheStreetXOMA (XOMA) Downgraded to D at TheStreet
www.americanbankingnews.com - April 10 at 7:31 AM
XOMA (XOMA) Raised to "Outperform" at WedbushXOMA (XOMA) Raised to "Outperform" at Wedbush
www.americanbankingnews.com - April 9 at 12:44 PM
$3.69 Million in Sales Expected for XOMA Co. (XOMA) This Quarter$3.69 Million in Sales Expected for XOMA Co. (XOMA) This Quarter
www.americanbankingnews.com - April 8 at 2:26 AM
XOMA (XOMA) Receives Hold Rating from Zacks Investment ResearchXOMA (XOMA) Receives Hold Rating from Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:26 PM
-$0.52 EPS Expected for XOMA Co. (XOMA) This Quarter-$0.52 EPS Expected for XOMA Co. (XOMA) This Quarter
www.americanbankingnews.com - April 6 at 5:10 PM
Form 8-K XOMA Corp For: Mar 30Form 8-K XOMA Corp For: Mar 30
www.streetinsider.com - April 5 at 8:39 AM
XOMA to Present at the H.C. Wainwright Global Life Sciences ConferenceXOMA to Present at the H.C. Wainwright Global Life Sciences Conference
feeds.benzinga.com - April 3 at 7:51 AM
XOMA (XOMA) Receives Buy Rating from HC WainwrightXOMA (XOMA) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 1 at 3:10 PM
Osteoarthritis Market Spotlight: 2018-2028 - Prevelent Cases Expected to Rise from 301 Mn in 2016, to 352 Mn by 2025Osteoarthritis Market Spotlight: 2018-2028 - Prevelent Cases Expected to Rise from 301 Mn in 2016, to 352 Mn by 2025
globenewswire.com - March 29 at 4:13 PM
Osteoarthritis Market Spotlight: 2018-2028 - Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and ...Osteoarthritis Market Spotlight: 2018-2028 - Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and ...
www.prnewswire.com - March 29 at 4:13 PM
LakePharma Appoints David Boyle To Chief Financial OfficerLakePharma Appoints David Boyle To Chief Financial Officer
www.prnewswire.com - March 26 at 4:19 PM
 Analysts Anticipate XOMA Co. (XOMA) Will Post Quarterly Sales of $3.69 Million Analysts Anticipate XOMA Co. (XOMA) Will Post Quarterly Sales of $3.69 Million
www.americanbankingnews.com - March 22 at 2:52 AM
XOMA Co. (XOMA) Expected to Announce Earnings of -$0.52 Per ShareXOMA Co. (XOMA) Expected to Announce Earnings of -$0.52 Per Share
www.americanbankingnews.com - March 20 at 7:10 PM
XOMA (XOMA) Stock Rating Lowered by Zacks Investment ResearchXOMA (XOMA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 17 at 10:31 AM
Q1 2018 Earnings Estimate for XOMA Co. Issued By Wedbush (XOMA)Q1 2018 Earnings Estimate for XOMA Co. Issued By Wedbush (XOMA)
www.americanbankingnews.com - March 16 at 7:34 AM
XOMA (XOMA) Rating Increased to Hold at ValuEngineXOMA (XOMA) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 10 at 7:42 PM
XOMA (XOMA) Downgraded by Zacks Investment ResearchXOMA (XOMA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 9 at 9:02 PM
XOMA (XOMA) Given a $49.00 Price Target at HC WainwrightXOMA (XOMA) Given a $49.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 9 at 6:56 PM
XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateXOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 8 at 11:05 AM
XOMA (XOMA) Announces Quarterly  Earnings Results, Beats Expectations By $0.19 EPSXOMA (XOMA) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - March 8 at 9:47 AM
XOMA to Present at the Cowen and Company 38th Annual Health Care ConferenceXOMA to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 10:51 AM
$4.12 Million in Sales Expected for XOMA Co. (XOMA) This Quarter$4.12 Million in Sales Expected for XOMA Co. (XOMA) This Quarter
www.americanbankingnews.com - March 5 at 4:18 AM
Bogle Investment Management L P DE Takes $3.66 Million Position in XOMA Co. (XOMA)Bogle Investment Management L P DE Takes $3.66 Million Position in XOMA Co. (XOMA)
www.americanbankingnews.com - March 4 at 4:58 AM
Zacks: Brokerages Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per ShareZacks: Brokerages Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - March 3 at 4:04 PM
XOMA (XOMA) Lowered to Hold at Zacks Investment ResearchXOMA (XOMA) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:11 PM
FDA Grants Agios' (AGIO) Leukemia Candidate Priority ReviewFDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
finance.yahoo.com - February 16 at 4:13 PM
Zacks: Brokerages Anticipate XOMA Co. (XOMA) to Post -$0.52 EPSZacks: Brokerages Anticipate XOMA Co. (XOMA) to Post -$0.52 EPS
www.americanbankingnews.com - February 14 at 9:06 PM
Cambridge biotech Enumeral files for bankruptcy, sells cancer drugs - Boston Business JournalCambridge biotech Enumeral files for bankruptcy, sells cancer drugs - Boston Business Journal
www.bizjournals.com - February 6 at 3:21 PM
Theravances NDA for COPD Candidate Gets FDA AcceptanceTheravance's NDA for COPD Candidate Gets FDA Acceptance
finance.yahoo.com - January 31 at 6:11 AM
XOMA (XOMA) versus Osiris Therapeutics (OSIR) Critical SurveyXOMA (XOMA) versus Osiris Therapeutics (OSIR) Critical Survey
www.americanbankingnews.com - January 30 at 7:12 PM
East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs - San Francisco Business TimesEast Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs - San Francisco Business Times
www.bizjournals.com - January 25 at 3:21 PM
East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugsEast Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs
finance.yahoo.com - January 25 at 3:21 PM
XOMA Co. (XOMA) Receives Average Recommendation of "Buy" from BrokeragesXOMA Co. (XOMA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 23 at 5:36 AM
XOMA (XOMA) Earns "Buy" Rating from HC WainwrightXOMA (XOMA) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 21 at 11:38 PM
XOMA Co. (XOMA) Expected to Post Quarterly Sales of $4.12 MillionXOMA Co. (XOMA) Expected to Post Quarterly Sales of $4.12 Million
www.americanbankingnews.com - January 14 at 3:38 PM
It was a banner year for stocks, but not everyone shared in the wealthIt was a banner year for stocks, but not everyone shared in the wealth
www.bizjournals.com - January 11 at 4:32 PM
It was a banner year for stocks, but not everyone shared in the wealth.It was a banner year for stocks, but not everyone shared in the wealth.
finance.yahoo.com - January 8 at 4:32 PM
XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General CounselXOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel
finance.yahoo.com - January 8 at 10:36 AM
It was a banner year for stocks, but not everyone shared in the wealth. Heres how Pittsburghs public companies fared.It was a banner year for stocks, but not everyone shared in the wealth. Here's how Pittsburgh's public companies fared.
www.bizjournals.com - January 7 at 12:31 PM
Anika Therapeutics Receives FDA Nod for Bone Repair TherapyAnika Therapeutics Receives FDA Nod for Bone Repair Therapy
finance.yahoo.com - January 3 at 9:45 AM
XOMA Co. (XOMA) Receives Consensus Rating of "Buy" from BrokeragesXOMA Co. (XOMA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 29 at 7:02 AM
Zacks: Analysts Expect XOMA Co. (XOMA) Will Announce Quarterly Sales of $4.12 MillionZacks: Analysts Expect XOMA Co. (XOMA) Will Announce Quarterly Sales of $4.12 Million
www.americanbankingnews.com - December 28 at 6:32 PM
ETFs with exposure to XOMA Corp. : December 27, 2017ETFs with exposure to XOMA Corp. : December 27, 2017
finance.yahoo.com - December 27 at 1:04 PM
Zacks: Analysts Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - December 26 at 11:28 AM
Head to Head Survey: XOMA (XOMA) versus SIGA Technologies (SIGA)Head to Head Survey: XOMA (XOMA) versus SIGA Technologies (SIGA)
www.americanbankingnews.com - December 24 at 11:28 AM
4 Biotech Stocks That More Than Doubled This Year - Nasdaq4 Biotech Stocks That More Than Doubled This Year - Nasdaq
www.nasdaq.com - December 22 at 6:35 PM
Brokers Set Expectations for XOMA Co.s Q1 2018 Earnings (XOMA)Brokers Set Expectations for XOMA Co.'s Q1 2018 Earnings (XOMA)
www.americanbankingnews.com - December 21 at 11:28 AM

SEC Filings

Xoma (NASDAQ:XOMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Xoma (NASDAQ:XOMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Xoma (NASDAQ XOMA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.